Education
About Us
Working with TipRanks
Follow Us
Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.18Last Year’s EPS
0.22Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: 26.67%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with significant achievements in study enrollment and strategic partnerships, but it is tempered by financial challenges and delays in study results. The financial position is strong, yet there is an increased R&D expense and a net loss. The sentiment is mixed, reflecting both optimism about Seralutinib's potential and concerns about financial and operational timelines.Company Guidance
During the Gossamer Bio Q1 2025 earnings call, significant guidance was provided on the progress of Seralutinib, particularly in the Phase III PROSERA study for pulmonary arterial hypertension (PAH). The company achieved a milestone by closing new patient screenings with 343 patients enrolled or scheduled to randomize, while targeting a demonstration of a significant treatment effect in the six-minute walk distance at 24 weeks. The study aims to complete by the fourth quarter, with top-line results expected in February 2026. The baseline characteristics of the enrolled patients, including a mean six-minute walk distance of 376 meters and an NT-proBNP level of 96 ng/L, align with targeted criteria to optimize treatment success. Additionally, 74% of enrolled patients are categorized as functional Class III, indicating a sicker population likely to show a more dramatic improvement. The company emphasized Seralutinib's potential for first-in-class treatment, leveraging its unique mechanism and promising safety profile to position it as a backbone therapy in PAH. Financially, Gossamer ended Q1 with $257.9 million in cash, projecting sufficient funds until the first half of 2027.PROSERA Study Enrollment Success
Gossamer Bio achieved a significant milestone by nearing the completion of enrollment for the PROSERA study with 343 patients. The baseline characteristics of the patients are exactly as targeted, enhancing the likelihood of success.
Strong Financial Position
Gossamer Bio ended the quarter with $257.9 million in cash and cash equivalents, providing sufficient capital until the first half of 2027.
Potential Global Expansion
Seralutinib's potential for regulatory approval in Japan is supported by its orphan drug designation and participation of Japanese patients in the PROSERA study.
Strategic Partnership with Chiesi Group
The collaboration with Chiesi Group enables Seralutinib to immediately enter a global registrational Phase III study for PH-ILD, with a shared cost basis of 50-50.
GOSS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GOSS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $1.05 | $1.04 | -0.95% |
Mar 13, 2025 | $1.30 | $1.45 | +11.54% |
Nov 07, 2024 | $0.89 | $0.88 | -1.12% |
Aug 12, 2024 | $0.80 | $0.82 | +2.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Gossamer Bio Inc (GOSS) report earnings?
Gossamer Bio Inc (GOSS) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Gossamer Bio Inc (GOSS) earnings time?
Gossamer Bio Inc (GOSS) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GOSS EPS forecast?
GOSS EPS forecast for the fiscal quarter 2025 (Q2) is -0.18.